Search clinical trials for: 125 mg Aprepitant

Total 12097 results

Merck Sharp & Dohme LLC

Completed

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Chemotherapy-Induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)

Chemotherapy Induced Nausea and Vomiting
The Hospital for Sick Children

Completed

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers

Chemotherapy-induced Nausea and Vomiting

Canada
Neuropore Therapies Inc.
Celerion

Completed

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

Healthy Volunteers

United States
Nuformix Technologies Limited

Completed

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

Healthy

United Kingdom
Pain Therapeutics
National Institute on Aging (NIA)

Completed

A Safety Study of PTI-125 in Healthy Volunteers

Alzheimer Disease | Alzheimer Disease, Early Onset

United States
Dartmouth-Hitchcock Medical Center

Completed

Differentiating the Effects of Substance P and Beta-endorphin

Chronic Obstructive Pulmonary Disease

United States
Albert Einstein College of Medicine
Jacobi Medical Center

Terminated

Low Dose Aprepitant for Patients Receiving Carboplatin

Chemotherapy-induced Nausea and Vomiting

United States
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Homoarginine Supplementation in Patients After Stroke (HiS)

Deficiency; Diet

Germany
Pain Therapeutics
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

Postoperative Nausea and Vomiting | Chemotherapy-Induced Nausea and Vomiting
Napo Pharmaceuticals, Inc.

Active, not recruiting

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy (OnTARGET)

Adult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related Diarrhea

United States, Taiwan, Georgia, Serbia, Argentina
Bausch Health Americas, Inc.

Completed

Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea (ADVENT)

HIV Associated Diarrhea

United States, Puerto Rico
GlaxoSmithKline

Completed

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

Gastroparesis

United States, Australia, Belgium, United Kingdom, Canada, Sweden
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
GTx

Completed

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Prostate Cancer

United States
Penn State University

Terminated

The Role of Satiety in the Effect of Portion Size on Intake

Feeding Behavior

United States
Cassava Sciences, Inc.
National Institute on Aging (NIA)

Completed

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients (PTI-125)

Alzheimer Disease

United States, Canada
Ake Norberg

Completed

A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA

Healthy | SIRS

Sweden
Universitaire Ziekenhuizen KU Leuven

Completed

Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.

Pruritus

Belgium
Cassava Sciences, Inc.
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States
Merck Sharp & Dohme LLC

Completed

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

Urinary Incontinence
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Janssen Sciences Ireland UC

Terminated

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA)

Respiratory Syncytial Virus Infections

United States, Belgium, Taiwan, Israel, Japan, Argentina, Malaysia, Korea, Republic of, Netherlands, Spain, Australia, Italy, Brazil, France, United Kingdom, Sweden, Bulgaria
Foresee Pharmaceuticals Co., Ltd.

Terminated

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Severe to Critical COVID 19 With Associated ARDS

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions

Healthy

Canada
Ipsen

Recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

United States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
Grifols Therapeutics LLC

Completed

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion (PRIORITY)

Arterial Occlusive Diseases

United States
Hoffmann-La Roche
Chugai Pharmaceutical Co.

Terminated

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (SAkuraBonsai)

Neuromyelitis Optica Spectrum Disorder | NMOSD

United States, Korea, Republic of, Italy, Canada, Japan, Turkey
Actavis Inc.

Completed

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions

Healthy

Canada
Eli Lilly and Company

Active, not recruiting

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Neoplasms, Hematologic

United States, Germany, Australia, Sweden, France, Spain, Italy, Austria, Canada
Manal Abdelmalek

Completed

JKB-121 for the Treatment of Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis

United States
Unither Pharmaceuticals, France
Raptim Research

Completed

Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML)

Acute Pain

India
Impax Laboratories, LLC

Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease (APEX-PD)

Parkinson's Disease

United States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine
Karolinska Institutet
Karolinska University Hospital; Region Stockholm

Completed

Albumin Kinetics in Generalized Inflammation

Major Abdominal Surgery

Sweden
Rush University Medical Center

Completed

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Nausea | Vomiting

United States
NYU Langone Health

Completed

A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

COVID-19

United States
Eli Lilly and Company

Completed

A Study in the Treatment of Osteoarthritis Knee Pain

Osteoarthritis Knee Pain

United States, Puerto Rico, Romania
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
Hoffmann-La Roche

Completed

A Study of RO4917523 in Patients With Fragile X Syndrome

Fragile X Syndrome

France, Spain, United States, Peru, Canada, United Kingdom, Chile, Argentina, Mexico, Sweden
GlaxoSmithKline

Completed

The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis

Gastroparesis

Belgium, Sweden
Taisho Pharmaceutical R&D Inc.

Terminated

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

Major Depressive Disorder

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Vifor (International) Inc.
Labcorp Drug Development Inc

Withdrawn

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Beta-Thalassemia

United States, Bulgaria, Israel
Merck Sharp & Dohme LLC

Completed

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Chemotherapy-Induced Nausea and Vomiting (CINV)
Bayer

Completed

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Heart Failure

Belgium, France, Switzerland, United States, Spain, Greece, Japan, Singapore, Austria, Germany, Korea, Republic of, Poland, Denmark, Israel, Netherlands, Taiwan, Bulgaria, Canada, Sweden, Czechia, Australia, Italy, Hungary, United Kingdom
Aquinox Pharmaceuticals (Canada) Inc.

Unknown

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome (LEADERSHIP 301)

Interstitial Cystitis | Painful Bladder Syndrome | Bladder Pain Syndrome | Chronic Interstitial Cystitis

United States, Belgium, Canada, Czechia, Denmark, Hungary, Latvia, Netherlands, Poland, Romania, Spain, United Kingdom
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

Nonalcoholic Steatohepatitis (NASH)

China
Biodel

Completed

Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration

Diabetes Mellitus

Search clinical trials for: 125 mg Aprepitant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations